Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0000875045
$240.98
-0.87% · delayed ~15 min
Last price from Oct 21, 2026
$35.38B market value
From BIOGEN INC.'s FY2025 10-K, filed Feb 6, 2026 · read the filing
BIOGEN develops and makes medicines. It took in $9.89B last year, which makes it a mid-sized company. Of every dollar it sells, about 13 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Strong finances across the board.
From BIOGEN INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$1.63B → $1.29B
Profit margin
16.9% → 13.1%
Free cash flow
$2.72B → $2.05B
Earnings per share
$11.19 → $8.81
Measured against FY2024, from the 10-K filed Feb 6, 2026
Deteriorated: -20.8%
$1.63B to $1.29BSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
BIIB fell 0.87% on the latest quote. The average Health Care company tracked here moved +1.53%, and the S&P 500 −1.04%. That is 2.4 points below its sector and in line with the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 5% a year for the next 10 years. Over the last 10 years it shrank by about 5% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 13 cents of every dollar of sales as profit, earning $1.29B last year.
Barely. Sales were roughly flat, up 2.2%.
No. At its current cash flow it could clear its debt in about 1.5 years. For every $1 it owes, it owns $2.63 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.29B and generated $2.20B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 6, 2026Filing for FY2025 | FY202410-K · Feb 6, 2026Filing for FY2024 | FY202310-K · Feb 6, 2026Filing for FY2023 | FY202210-K · Feb 15, 2023Filing for FY2022 | FY202110-K · Feb 3, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | +2.2% |
| Cost of revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | +4.1% |
| Gross profit | $7.49B† | $7.37B† | $7.30B† | $7.90B† | $8.87B† | +1.6% |
| Gross marginGross profit ÷ revenueWhat is this? | 75.7% | 76.1% | 74.2% | 77.6% | 80.8% | −0.4 pts |
| Selling, general and administrative | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | +1.2% |
| Operating income | — | — | — | — | $2.84B | — |
| Operating marginOperating income ÷ revenueWhat is this? | — | — | — | — | 25.9% | — |
| Interest expense | $267.5M | $250.3M | $246.9M | $246.6M | $253.6M | +6.9% |
| Income before tax | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B | −18.3% |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | −20.8% |
| Net marginNet income ÷ revenueWhat is this? | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | −3.8 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $8.81 | $11.19 | $8.01 | $21.16 | $10.59 | −21.3% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| BIIBBIOGEN INC. · this page | 9.0/10 | 6/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 27 shares
Holds 1,467 shares after this filing.
Had shares withheld to cover taxes — 8 shares at $219.88 ($1.8K)
Holds 1,459 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report on Form 10-Q
Read the filingPublished results
Read the filingWrite down why you are following BIOGEN INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 91 subsidiaries named in its 10-K, incorporated across 45 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from BIIB's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 6, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 6/9 | 10-K, filed Feb 6, 2026 |
| FY2024 | 8.0 | 7/9 | 10-K, filed Feb 12, 2025 |
| FY2023 | 7.0 | 4/9 | 10-K, filed Feb 14, 2024 |
| FY2022 | 7.0 | 6/9 | 10-K, filed Feb 15, 2023 |
| FY2021 | 8.0 | 5/9 | 10-K, filed Feb 3, 2022 |
| FY2020 | 8.0 | 7/9 | 10-K, filed Feb 3, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
3.65
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.62
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −3.8 pts
16.9% to 13.1%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: -24.7%
$2.72B to $2.05BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: -21.3%
$11.19 to $8.81Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +26.7%
$2.38B to $3.01BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q1 FY2026 against Q1 FY2025, from the 10-Q filed Apr 29, 2026 — read it.
Improved: +167.5%
$222.2M to $594.3MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +32.8%
$240.5M to $319.5MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +3.0 pts
9.9% to 12.9%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +31.9%
$1.65 to $2.17Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +38.2%
$4.55B to $6.29BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +30.2%
$2.60B to $3.38BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +38.0%
$37.1M to $51.2MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
6 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 3% and 7%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 43 analysts covering this company, as of . Their views, not this site's.
Of 43 analysts publishing on this company, 10 say strong buy, 19 say buy, 13 say hold and 1 say sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 4.1% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 21.3x — investors pay $21.3 for each $1 of trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 2.2% |
| 13.1% |
| 27.36x |
| 0.61x |
| REGNREGENERON PHARMACEUTICALS, INC. | 8.7/10 | 6/8 | 1.0% | 31.4% | 19.02x | 0.30x |
|---|
| MRNAModerna, Inc. | 6.0/10 | 3/9 | -39.9% | -145.2% | — | 0.43x |
|---|
| ALNYALNYLAM PHARMACEUTICALS, INC. | 7.3/10 | 5/8 | 65.2% | 8.4% | 95.89x | 5.29x |
|---|
| INCYINCYTE CORP | 10.0/10 | 6/8 | 21.2% | 25.0% | 18.04x | 0.35x |
|---|
| Median of peers | 8.0/10 | — | 11.1% | 16.7% | 19.02x | 0.39x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 593 shares at $203.34 ($120.6K)
Holds 3,282 shares after this filing.
Sold on the open market — 593 shares at $200.96 ($119.2K)
Holds 2,689 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 593 shares ($119.2K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 593 shares ($120.6K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Published results
Held a shareholder vote
Read the filingAttached financial statements or exhibits
Read the filingSigned a material agreement · Completed an acquisition or disposal · Took on a direct financial obligation · Made a Regulation FD disclosure
Read the filingQuarterly report for Q1 FY2026
Profit margin +3.0 pts · Free cash flow +167.5% · Profit +32.8% — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingPublished results
Read the filingSigned a material agreement · Reported another event
Read the filingHad a director or senior officer leave or join
Read the filingHad a director or senior officer leave or join · Reported another event
Read the filingAnnual report for FY2025
Profit margin −3.8 pts · Profit -20.8% · Free cash flow -24.7% — against FY2024
Read the filingPublished results
Read the filingPublished results
Read the filingQuarterly report for Q3 FY2025
Profit margin +2.6 pts · Cash +127.3% · Profit +20.1% — against Q3 FY2024
Read the filingPublished results
Read the filingPublished results
Read the filingPublished results
Read the filingThe first 40 of 91. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-06. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3
Yahoo ·
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Yahoo ·
B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244
Benzinga ·
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Yahoo ·
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
Yahoo ·
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
SeekingAlpha ·
TD Cowen Maintains Buy on Biogen, Raises Price Target to $250
Benzinga ·
RBC Capital names top healthcare stocks as sector upgraded to overweight
Yahoo ·
S&P 500 Top Movers: Gainers and Losers From Today's US Session
ChartMill ·
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Yahoo ·
Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310
Benzinga ·
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
Yahoo ·
Primary sources and further research